All In Biotech

Drug Trial Radar · NCT01713946

A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures

A Three-arm, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Two Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) Who Have Refractory Partial-onset Seizures

Last checked: Nov 19, 2026Latest source record: Nov 7, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 366 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

366

Actual

Start

Apr 29, 2013

Primary completion

Oct 25, 2017

Study completion Oct 25, 2017

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 25, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluated the efficacy and safety of two trough-ranges of everolimus given as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who had refractory partial-onset seizures. The study consisted of 4 phases for each patient Baseline phase:\[From Screening Week -8 (V1) to randomization visit at Week 0 (V2)\], Core phase \[from randomization at Week 0 (V2) to Week 18 (V11)\], Extension phase \[from Week 18 (V11) until 48 weeks after the last patient had completed the core phase\] and Post Extension phase \[from end of Extension phase to end of study\].

Conditions

  • Tuberous Sclerosis Complex-associated Refractory Seizures

Interventions

  • RAD001Drug

    Everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.

  • PlaceboDrug

    Placebo tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.

  • Antiepileptic drug (1 to 3 only)Drug

    no more than any 3 of the listed antiepileptic drugs could be taken with the study drug or placebo. List of allowed antiepileptic drugs were: valporic acid, carbamazepine, clobazam, N-desmethylclobazam, topiramate,TRI477, TRI476, clonazepam, zonisamide, phenobarbital, phenytoin

  • open label RAD001 (only used for post-extension phase)Drug

    everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister backs in boxes with open label design and were taken during the Post-Extension phase, where all the participants, including those who were previously on placebo, took the 2mg tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Core Phase: European Medicine Agency (EMA): Seizure Frequency Response RateTime frame: Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)
  2. Core Phase: Food & Drug Administration (FDA): Percentage Change From Baseline in Partial Onset-seizure FrequencyTime frame: Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)

Locations

104 sites in 25 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham SC

    Birmingham, Alabama

  • TGen/APNNA

    Phoenix, Arizona

  • University of California at Los Angeles SC

    Los Angeles, California

  • Children's Hospital Oakland SC

    Oakland, California

  • Children's Hospital of Orange County SC

    Orange, California

  • Rady Children's Hospital SC

    San Diego, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Connecticut Childrens Medical Center SC

    Hartford, Connecticut

  • University of Chicago SC - 2

    Chicago, Illinois

  • Kennedy Krieger Institute SC

    Baltimore, Maryland

  • Children's Hospital Boston SC

    Boston, Massachusetts

  • Minnesota Epilepsy Group - PA SC

    Saint Paul, Minnesota

  • Washington University School of Medicine SC-2

    St Louis, Missouri

  • Morristown Memorial Hospital SC-2

    Morristown, New Jersey

  • New York University Medical Center SC-3

    New York, New York

  • Cincinnati Children's Hospital Medical Center SC

    Cincinnati, Ohio

  • Oregon Health and Science University SC - 3

    Portland, Oregon

  • Children's Hospital of Philadelphia SC

    Philadelphia, Pennsylvania

  • LeBonheur Childrens Medical Group SC

    Memphis, Tennessee

  • Texas Scottish Rite Hospital for Children Texas Scottish

    Dallas, Texas

  • Texas Children s Hospital SC

    Houston, Texas

  • The University of Texas Medical School-Houston SC

    Houston, Texas

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Randwick, New South Wales, Australia

  • Novartis Investigative Site

    Parkville, Victoria, Australia

  • Novartis Investigative Site

    Perth, Western Australia, Australia

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Ghent, Belgium

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Jette, Brussels Capital, Belgium

  • Novartis Investigative Site

    Vancouver, British Columbia, Canada

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Bogotá, Colombia

  • Novartis Investigative Site

    Medellín, Colombia

  • Novartis Investigative Site

    Cali, Valle del Cauca Department, Colombia

  • Novartis Investigative Site

    Aarhus, Denmark

  • Novartis Investigative Site

    Amiens, France

  • Novartis Investigative Site

    Angers, France

Showing 40 of 104 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.